VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),…
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025…
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025…
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025…
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence…
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence…
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence…
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…